Peer-reviewed veterinary case report
Latanoprost eye drops lower eye pressure in cats with glaucoma
By McDonald, Jessica E et al.·Published in Veterinary ophthalmology·2016·Department of Ophthalmology & Visual Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Effect of topical latanoprost 0.005% on intraocular pressure and pupil diameter in normal and glaucomatous cats.
- Species:
- cat
Plain-English summary
A group of 12 adult cats, including six with inherited primary congenital glaucoma (PCG), were treated with a medication called latanoprost to see how it affected their eye pressure and pupil size. The cats received the treatment in one eye while the other eye was used as a control. The results showed that latanoprost significantly lowered eye pressure in the cats with glaucoma for several hours after treatment, but the effect lessened over time. While the medication caused the pupils to constrict initially, they dilated again after 24 hours. More studies are needed to see if latanoprost can be a long-term solution for managing eye pressure in cats with glaucoma.
People also search for: cat glaucoma treatment · latanoprost for cats · cat eye pressure medication
Abstract
OBJECTIVE: To determine the effects of latanoprost on intraocular pressure (IOP) and pupil diameter (PD) in cats with inherited primary congenital glaucoma (PCG) and normal cats. ANIMALS STUDIED AND PROCEDURES: IOP and PD were measured in both eyes (OU) of 12 adult cats (six normal, six PCG), three times per week for 3 weeks prior to, for 3 weeks during, and for 2 weeks following twice-daily treatment with 0.005% latanoprost to the right eye (OD) and vehicle to the left (control) eye (OS). IOP and PD were measured hourly, for 8 h, 1 day prior to, and on the first and last days of treatment. Aqueous humor flow rate (AHF) was determined at baseline and at the end of the treatment phase in six normal cats. RESULTS: Mean IOP was significantly lower in treated vs. control eyes of PCG cats, for up to 8 h following a single latanoprost treatment, and a maximal IOP reduction of 63% occurred in treated eyes at 3 h. Latanoprost acutely lowered IOP in cats with PCG, but this effect appeared to diminish over 3 weeks of treatment. AHF was modestly increased in the treated eyes of normal cats after 3 weeks of latanoprost treatment, although IOP was not significantly affected. Latanoprost caused miosis, with rebound mydriasis at 24 h posttreatment, in the treated eyes of all cats. CONCLUSIONS: Further research is needed to determine the suitability and efficacy of latanoprost treatment for long-term IOP-lowering in cats with PCG or other forms of glaucoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/26183373/